Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;14(1):47-61.
doi: 10.1007/s13300-022-01350-9. Epub 2022 Dec 9.

Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis

Hong Wang #  1   2 , Xiaoya Xie #  3 , Quannan Zu  4 , Ming Lu  4 , Rongfa Chen  5 , Zhiren Yang  5 , Yongqiang Gao  6 , Zhangui Tang  7
Affiliations
Review

Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis

Hong Wang et al. Diabetes Ther. 2023 Jan.

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of coronary artery disease (CAD). In patients with acute coronary syndrome (ACS), guidelines recommend a potent P2Y12 inhibitor in addition to aspirin. For those with complicated and advanced CAD requiring complex percutaneous coronary intervention (PCI), the risk for adverse ischemic events is even higher. Prolonged dual antiplatelet therapy (DAPT) use is controversial. A new antiplatelet regimen after PCI should be considered. In this analysis, we aimed to systematically show the impact of long-term ticagrelor monotherapy after a short course of DAPT use on the outcomes in patients with T2DM following PCI.

Methods: Electronic databases were searched for relevant publications. Studies that were based on patients with T2DM and that included patients with T2DM were selected on the basis of the inclusion and exclusion criteria. Statistical analysis was carried out with RevMan software. The data are presented as risk ratios (RR) with 95% confidence intervals (CI).

Results: A total of 8621 patients were included in this analysis, whereby 4357 participants with T2DM were assigned to ticagrelor monotherapy and 4264 were assigned to DAPT. Our results showed long-term ticagrelor monotherapy after a short course of DAPT use to be associated with a significantly lower risk of major adverse cardiac events (RR 0.86, 95% CI 0.77-0.98; P = 0.02) and all-cause mortality (RR 0.77, 95% CI 0.60-0.98; P = 0.03). However, no significant difference was observed in cardiac death, myocardial infarction, stroke, stent thrombosis, or repeated revascularization. Ticagrelor monotherapy was associated with significantly lower risk of thrombolysis in myocardial infarction (TIMI) defined minor or major bleeding (RR 0.71, 95% CI 0.54-0.93; P = 0.01) compared with the DAPT regimen.

Conclusion: Long-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.

Keywords: Bleeding; Dual antiplatelet therapy; Monotherapy; Percutaneous coronary intervention; Ticagrelor; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram representing the study selection
Fig. 2
Fig. 2
Forest plot showing the comparison of cardiovascular outcomes between ticagrelor monotherapy and dual antiplatelet therapy following PCI in patients with T2DM
Fig. 3
Fig. 3
Forest plot showing the comparison of minor bleeding and TIMI bleeding between ticagrelor monotherapy and dual antiplatelet therapy following PCI in patients with T2DM
Fig. 4
Fig. 4
Forest plot showing the comparison of BARC bleeding between ticagrelor monotherapy and dual antiplatelet therapy following PCI in patients with T2DM
Fig. 5
Fig. 5
Funnel plot showing publication bias (A)
Fig. 6
Fig. 6
Funnel plot showing publication bias (B)
See this image and copyright information in PMC

References

    1. Mishra S, Ray S, Dalal JJ, et al. Management standards for stable coronary artery disease in India. Indian Heart J. 2016;68(Suppl 3):S31–S49. doi: 10.1016/j.ihj.2016.11.320. - DOI - PMC - PubMed
    1. Das RN. Relationship between diabetes mellitus and coronary heart disease. Curr Diabetes Rev. 2016;12(3):285–296. doi: 10.2174/1573399812666160105111811. - DOI - PubMed
    1. Jensen ES, Olesen KKW, Gyldenkerne C, et al. Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016. BMC Cardiovasc Disord. 2021;21(1):579. doi: 10.1186/s12872-021-02312-y. - DOI - PMC - PubMed
    1. Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915–2931. doi: 10.1016/j.jacc.2018.09.057. - DOI - PubMed
    1. Savarese G, Savonitto S, Lund LH, et al. Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85,265 patients. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):218–228. doi: 10.1093/ehjcvp/pvw011. - DOI - PubMed

LinkOut - more resources